MDwise Self-Administered Codes for Medical

Similar documents
Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin

DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364

Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or

Drug Name Tier Drug Name Tier

Medicare Part B Covered Medications

Thank you for your request for information that has been processed under reference number

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Self-Injected Medications and Disposal Recommendations

SELF-ADMINISTERED MEDICATIONS LIST

Immune Modulating Drugs Prior Authorization Request Form

Advantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Cimzia. Cimzia (certolizumab pegol) Description

Stelara. Stelara (ustekinumab) Description

Cosentyx. Cosentyx (secukinumab) Description

CIMZIA (certolizumab pegol)

Otezla. Otezla (apremilast) Description

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

ACTEMRA (tocilizumab)

Generic (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

2010 Drugs Requiring Prior Authorization

List of Designated High-Cost Drugs

Subject: Palonosetron Hydrochloride (Aloxi )

TRICARE Uniform Formulary. Pre-Authorization Requirements

Medicare Part C Medical Coverage Policy

Prescription Drug Benefit Rider V

The following are J Code requirements

Cigna Drug and Biologic Coverage Policy

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

See Important Reminder at the end of this policy for important regulatory and legal information.

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Drug Use Evaluation: Physician Administered Drugs (PADs)

Divya Jain Arwindekar, DO Transplant Nephrologist Advocate Christ Medical Center & Associates in Nephrology

Prescription Drug Benefit Rider

30. Beta Adrenergic Receptor Blocking Agents Acebutolol Carteolol (Cartrol) February 12, 2003 Penbutolol (Levatol) Propranolol (Inderal LA)

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

ACAMPROSATE (CAMPRAL)

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Do you or did you have any family members who have been diagnosed with MS? Yes No I Don t Know. Yes identical Yes not identical No

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents

See Important Reminder at the end of this policy for important regulatory and legal information.

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009

Amerigroup Washington, Inc. to conduct postservice reviews of certain modifiers and services

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid

Network Health Insurance Corporation 2013 P A Criteria

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

Alprazolam 0.25mg, 0.5mg, 1mg tablets

CHAPTER 7 SECTION 7.1 DRUGS AND MEDICINES TRICARE/CHAMPUS POLICY MANUAL M DEC 1998 OTHER SERVICES

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

Corporate Medical Policy

Humatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)

A9542 A9543 A9545 A9699 J0120 J0128 J0129 J0130

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

See Important Reminder at the end of this policy for important regulatory and legal information.

Cigna Drug and Biologic Coverage Policy

Actemra. Actemra (tocilizumab) Description

Download full Test Bank for Focus on Nursing Pharmacology 6th Edition by Karch

Drug Therapy Guidelines

2011 Medicare National Preferred 4 Tier PA Criteria

Objectives. The Immune Response. Mechanisms of T-Cell Activation. Balancing Act of Transplant 4/22/2015. Maintenance Immunosuppression

Step Therapy Criteria 2019

ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017

See Important Reminder at the end of this policy for important regulatory and legal information.

Issue Date: December 29, 1982 Authority: 32 CFR 199.4(b)(2)(v), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), and (e)(11)(i)

Q&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend

Subject: Ondansetron HCl (Zofran ) Injection

Pharmacy Management Drug Policy

Medications in the Solid Organ Transplant Recipient

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

Michigan Department of Health & Human Services Quantity Limitations

2011 Medicare National Preferred 4 Tier PA Criteria

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013

Update on antiemetics, what is new and future directions. Karin Jordan University of Halle

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

GROWTH HORMONE THERAPY

Transcription:

The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively to the pharmacy benefit effective 4/1/2018. At that time, medication should only be sourced from a contracted retail or specialty pharmacy. To do so, the provider should generate a prescription for the desired medication, and the dispensing pharmacy will submit a claim through the point-of-sale system. Please note that UM criteria may apply for pharmacy claims processing. Prior authorization requests may be faxed to the MDwise Pharmacy Benefit Manager, MedImpact, at (858) 790-7100. J0135 Injection, adalimumab, 20 mg Humira J0270 Injection, alprostadil, 1.25 mcg Caverject, Edex J0275 Alprostadil urethral suppository Muse J0571 Buprenorphine, oral, 1 mg Subutex J0572 Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine Bunavail, Suboxone, Zubsolv J0573 Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine Bunavail, Suboxone, Zubsolv J0574 Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine Bunavail, Suboxone, Zubsolv J0575 Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine Bunavail, Suboxone, Zubsolv J0604 Cinacalcet, oral, 1 mg, (for ESRD on dialysis) Sensipar J0630 Injection, calcitonin salmon, up to 400 units Calcimar, Miacalcin J0717 Injection, certolizumab pegol, 1 mg Cimzia J1324 Injection, enfuvirtide, 1 mg Fuzeon J1438 Injection, etanercept, 25 mg Enbrel J1595 Injection, glatiramer acetate, 20 mg Copaxone J1815 Injection, insulin, per 5 units Ademlog, Apidra, Basaglar, Humalog, Humulin, Lantus, Levemir, Novolin, NovoLog J1817 Insulin for administration through DME (i.e., insulin pump) per 50 units Apidra, Humalog, Humulin, Novolin, Novolog J1826 Injection, interferon beta-1a, 11 mcg for intramuscular use Avonex, Rebif J1830 Injection, interferon beta-1b, 0.25 mg Betaseron, Extavia J2170 Injection, mecasermin, 1 mg Iplex, Increlex

J2940 Injection, somatrem, 1 mg Protropin J2941 Injection, somatropin, 1 mg Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Tev-Tropin, Zorbtive J3030 Injection, sumatriptan succinate, 6 mg Imitrex J3110 Injection, teriparatide, 10 mcg Forteo J3357 Ustekinumab, for subcutaneous injection, 1 mg Stelara (SC only) J7303 Contraceptive supply, hormone containing vaginal ring, each NuvaRing J7304 Contraceptive supply, hormone containing patch, each OrthoEvra, Xulane J7342 Installation, ciprofloxacin otic suspension, 6 mg Cipro Otic J7500 Azathioprine, oral, 50 mg Azasan, Imuran J7502 Cyclosporine, oral, 100 mg Gengraf, Neoral, Sandimmune J7503 Tacrolimus, extended release, (Envarsus XR), oral, 0.25 mg Envarsus XR J7506 Prednisone, oral, per 5mg prednisone J7507 Tacrolimus, immediate release, oral, 1 mg Hecoria, Prograf J7508 Tacrolimus, extended release, oral, 0.1 mg Astagraf XL J7509 Methylprednisolone oral, per 4 mg Medrol J7510 Prednisolone oral, per 5 mg Millipred, Orapred, Pediapred, Veripred J7512 Prednisone, immediate release or delayed release, oral, 1 mg Deltasone, Rayos J7515 Cyclosporine, oral, 25 mg Gengraf, Neoral, Sandimmune J7517 Mycophenolate mofetil, oral, 250 mg Cellcept J7518 Mycophenolic acid, oral, 180 mg Myfortic J7520 Sirolimus, oral, 1 mg Rapamune J7527 Everolimus, oral, 0.25 mg Zortress J8498 Antiemetic drug, rectal/suppository, NOS <various> J8499 Prescription drug, oral, non-chemotherapeutic, NOS <various> J8501 Aprepitant, oral, 5 mg Emend J8510 Busulfan, oral, 2 mg Myleran J8515 Cabergoline, oral, 0.25 mg cabergoline J8520 Capecitabine, oral, 150 mg Xeloda J8521 Capecitabine, oral, 500 mg Xeloda J8530 Cyclophosphamide, oral, 25 mg cyclophosphamide

J8540 Dexamethasone, oral, 0.25 mg dexamethasone J8560 Etoposide; oral, 50 mg etoposide J8562 Fludarabine phosphate, oral, 10 mg fludarabine phosphate J8565 Gefitinib, oral, 250 mg Iressa J8597 Antiemetic drug, oral, NOS <various> J8600 Melphalan, oral, 2 mg Alkeran J8610 Methotrexate, oral, 2.5 mg Rheumatrex, Trexall J8650 Nabilone, oral, 1 mg Cesamet J8655 Netupitant 300 mg and palonosetron 0.5 mg Akynzeo J8670 Rolapitant, oral, 1 mg Varubi J8700 Temozolomide, oral, 5 mg Temodar J8705 Topotecan, oral, 0.25 mg Hycamtin J8999 Prescription drug, oral, chemotherapeutic, NOS <various> J9212 Injection, interferon alfacon-1, recombinant, 1 microgram Infergen J9213 Injection, interferon, alfa-2a, recombinant, 3 million units Roferon A J9214 Injection, interferon, alfa-2b, recombinant, 1 million units Intron-A J9216 Injection, interferon, gamma-1b, 3 million units Actimmune Q0144 Azithromycin dihydrate, oral, capsules/powder, 1 gram azithromycin dihydrate Q0161 Chlorpromazine hydrochloride, 5 mg, oral, FDA approved prescription chlorpromazine hydrochloride Q0162 Ondansetron 1 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of ondansetron chemotherapy treatment, not to exceed a 48 Q0163 Diphenhydramine hydrochloride, 50 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at time of chemotherapy treatment not to exceed a diphenhydramine hydrochloride 48 Q0164 Prochlorperazine maleate, 5 mg, oral, FDA approved prescription prochlorperazine maleate

Q0165 Prochlorperazine maleate, 10 mg, oral, fda approved prescription antiemetic, for use as a complete therapeutic substitute for an iv anti-emetic hour prochlorperazine maleate dosage Q0166 Granisetron hydrochloride, 1 mg, oral, FDA approved prescription at the time of chemotherapy treatment, not to exceed a 24 granisetron hydrochloride Q0167 Dronabinol, 2.5 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the dronabinol Q0168 Dronabinol, 5 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of dronabinol chemotherapy treatment, not to exceed a 48 Q0169 Promethazine hydrochloride, 12.5 mg, oral, FDA approved prescription promethazine hydrochloride Q0170 Promethazine hydrochloride, 25 mg, oral, fda approved prescription promethazine hydrochloride Q0171 Chlorpromazine hydrochloride, 10 mg, oral, fda approved prescription chlorpromazine hydrochloride Q0172 Chlorpromazine hydrochloride, 25 mg, oral, fda approved prescription chlorpromazine hydrochloride Q0173 Trimethobenzamide hydrochloride, 250 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 trimethobenzamide hydrochloride

Q0174 Thiethylperazine maleate, 10 mg, oral, FDA approved prescription thiethylperazine maleate Q0175 Perphenazine, 4 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the perphenazine Q0176 Perphenazine, 8 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the perphenazine Q0177 Hydroxyzine pamoate, 25 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic hydroxyzine pamoate Q0178 Hydroxyzine pamoate, 50 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic hydroxyzine pamoate Q0180 Dolasetron mesylate, 100 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 24 dolasetron mesylate Q0181 Unspecified oral dosage form, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for a IV anti-emetic at the <various> Q0510 Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant N/A Q0511 Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period N/A Q0512 Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period N/A

Q0513 Pharmacy dispensing fee for inhalation drug(s); per 30 days N/A Q0514 Pharmacy dispensing fee for inhalation drug(s); per 90 days N/A Q3025 Injection, interferon beta-1a, 11 mcg for intramuscular use Avonex, Rebif Q3026 Injection, interferon beta-1a, 11 mcg for subcutaneous use Avonex, Rebif Q3027 Injection, interferon beta-1a, 1 mcg for intramuscular use Avonex, Rebif Q3028 Injection, interferon beta-1a, 1 mcg for subcutaneous use Avonex, Rebif Q9981 Rolapitant, oral, 1 mg Varubi HHW-HIPP0539(1/18)